Skip to main content
Clinical Trials/KCT0009573
KCT0009573
Not yet recruiting
未知

Randomized, double-blinded, crossover clinical trial comparing characteristics and satisfaction of single-implant prostheses fabricated with multi-layer zirconia block

Yonsei University Health System, Dental Hospital0 sites26 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Yonsei University Health System, Dental Hospital
Enrollment
26
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Yonsei University Health System, Dental Hospital

Eligibility Criteria

Inclusion Criteria

  • · Individuals aged 19 years or older
  • · Those requiring a single\-implant prosthesis in the maxillary or mandibular anterior and first premolar regions
  • · Individuals who have signed the clinical trial consent form

Exclusion Criteria

  • · Individuals who cannot read the consent form
  • · Individuals without adjacent teeth in the area where the single\-implant prosthesis will be placed
  • · Individuals with uncontrolled systemic diseases
  • · Individuals with hypersensitivity to titanium or zirconia materials
  • · Individuals whose participation is deemed inappropriate by the principal research investigator due to clinically significant medical findings

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Double-blind, randomized, controlled, clinical trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19COVID-related Acute Respiratory Distress SyndromeMedDRA version: 21.1Level: PTClassification code 10001052Term: Acute respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 23.0Level: PTClassification code 10084268Term: COVID-19System Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-002193-27-ESCristina Avendano-Sola20
Active, not recruiting
Phase 1
Clinical trial to evaluate and compare the efficacy and safety of Hemorrane® Plus
EUCTR2019-003024-20-ESFAES FARMA SA185
Active, not recruiting
Phase 1
Clinical trial to evaluate if treatment with calcifediol (vitamin D analog) reduces the number of hospital admissions in patients with COVID-19.
EUCTR2021-000316-31-ESFAES FARMA S.A.804
Active, not recruiting
Phase 1
Study to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.Multiple sclerosisMedDRA version: 15.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2012-001965-34-ESServicio de Neurología, HU. Germans Trias i Pujol
Active, not recruiting
Phase 1
clinical trial or the anti-inflammatory effects of Curazink for 8 weeks in elderly patients with mild cognitive impairment in Alzheimer's disease or in patients with mild Alzheimer's diseaseIncluded are patients with the presence of a moderate or pronounced zinc deficienc and the diagnosis of a mild cognitive disorder, which may be due to an additional investigation (amyloid PET and / or cerebrospinal fluid) in the context of already performed diagnostic clarification an Alzheimer's pathology.Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2018-000342-19-DEOtto-von-Guericke-Universität Magdeburg, Medizinische Fakultät40